Regulus doubles on single-dose hepatitis C data
This article was originally published in Scrip
Executive Summary
It's far too early to know whether Regulus Therapeutics has a therapy that could compete with the new crop of blockbuster drugs that treat the hepatitis C virus (HCV), but the company's stock price doubled on 22 October based on impressive single-dose results from an ongoing Phase I clinical trial for RG-101.